FDA's Denial of Alemtuzumab Stirs Controversy
Did the agency wrongly emphasize unfavorable results?
Did the agency wrongly emphasize unfavorable results?
The U.S. Food and Drug Administration's denial of approval for alemtuzumab for treating RRMS is...
Clinical Research, Drug Development